Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer

BACKGROUND: Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among mCSPC patients is highly variable, while there is a lack of predictive markers of therapeutic benefit. Furthermore, there is li...

Descripción completa

Detalles Bibliográficos
Autores principales: Briones, Juan, Khan, Maira, Sidhu, Amanjot K., Zhang, Liying, Smoragiewicz, Martin, Emmenegger, Urban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138065/
https://www.ncbi.nlm.nih.gov/pubmed/34026638
http://dx.doi.org/10.3389/fonc.2021.658331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138065/
https://www.ncbi.nlm.nih.gov/pubmed/34026638
http://dx.doi.org/10.3389/fonc.2021.658331

Ejemplares similares